Shots:
- Capricor Therapeutics has reported the topline P-III (HOPE-3) trial data assessing Deramiocel (IV, Q3M) vs PBO in boys & young men (n=106) with DMD for 12mos. across the US
- Trial met its 1EP with a 54% slowing of upper-limb functional decline (PUL v2.0) among 105 evaluable pts at 12mos. & achieved its 2EP with a 91% reduction in LVEF deterioration (evaluable pts=83); data to be presented & published in future
- Additionally, the company is planning to submit its response to the CRL, incl. the HOPE-3 data, in line with its earlier alignment with the FDA
Ref: Capricor | Image: Capricor | Press Release
Related News: Santhera Pharmaceuticals Reports Health Canada’s Approval of Agamree (Vamorolone) to Treat Duchenne Muscular Dystrophy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
